The eyes as a window into disease prevention

Neurology

Volumn 67, Issue 3, 2006, Pages 376-377

  Biglan, Kevin M ^a,c   Halmagyi, Michael ^b  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^c UNIVERSITY OF ROCHESTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

ACCURACY; CLINICAL EXAMINATION; DIAGNOSTIC VALUE; DISEASE COURSE; DISEASE MARKER; EDITORIAL; ELECTROOCULOGRAPHY; EYE MOVEMENT; GENE MUTATION; HETEROZYGOTE; HUNTINGTON CHOREA; INFRARED SPECTROSCOPY; LATENT PERIOD; NEUROPROTECTION; OUTCOME ASSESSMENT; PREDICTION; PREVENTION STUDY; PREVENTIVE MEDICINE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RATING SCALE; RISK ASSESSMENT; SACCADIC EYE MOVEMENT; SAMPLE SIZE; SENSITIVITY ANALYSIS; SYMPTOMATOLOGY; TREATMENT INDICATION; VALIDATION STUDY;

EYE; EYE DISEASES; HUMANS; MACULAR DEGENERATION;

EID: 33747077181     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000232764.18332.b6     Document Type: Editorial

References (7)

1. Huntington Study Group. A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease. Neurology 2001;57:397-404.
2. Aylward EH, Sparks BF, Field KM, et al. Onset and rate of striatal atrophy in preclinical Huntington disease. Neurology 2004;63:66-72.
3. Blekher T, Johnson SA, Marshall J, et al. Saccades in presymptomatic and early stages of Huntington disease. Neurology 2006;67:394-399.
4. Golding CVP, Danchaivijitr C, Hodgson TL, Tabrizi SJ, Kennard C. Identification of an oculomotor biomarker of preclinical Huntington disease. Neurology 2006;67:485-487.
5. The Huntington Study Group PHAROS Investigators. At risk for Huntington disease: The PHAROS (Prospective Huntington At-Risk Observational Study) cohort enrolled. Arch Neurol 2006; 63:991-996.
6. Paulsen JS, Hayden M, Stout JC, et al. Preparing for preventive clinical trials: The Predict-HD study. Arch Neurol 2006;63:883-890.
7. Downing GJ. Biomarkers and surrogate endpoints in clinical research: definitions and conceptual model. In: Downing GJ, ed. Biomarkers and surrogate endpoints: clinical research and applications: proceedings of the NIH-FDA conference held on 15-16 April 1999. First ed. New York: Elsevier Science; 2000:1-9.